United States

Hypera SA (HYPE3.SA)

HYPE3.SA on Sao Paulo Stock Exchange

19 Oct 2018
Change (% chg)

R$ 0.31 (+1.04%)
Prev Close
R$ 29.79
R$ 29.96
Day's High
R$ 30.37
Day's Low
R$ 29.68
Avg. Vol
52-wk High
R$ 38.07
52-wk Low
R$ 25.31

Chart for


Hypera SA, formerly Hypermarcas SA, is a Brazil-based company engaged in the pharmaceuticals sector. The Company’s major business units include Branded Prescription, Consumer Health and Branded Generics. Branded Prescription is present in the main therapeutic classes in Brazil and it operates in the Primary Care segment under... (more)


Beta: 0.59
Market Cap(Mil.): R$ 19,118.88
Shares Outstanding(Mil.): 632.24
Dividend: 0.20
Yield (%): 1.86


  HYPE3.SA Industry Sector
P/E (TTM): 16.18 29.75 32.14
EPS (TTM): 1.87 -- --
ROI: 13.80 13.18 12.83
ROE: 15.10 15.14 14.95

Brazil's Hypera controlling shareholder in plea deal talks-report

RIO DE JANEIRO, Oct 3 The controlling shareholder of Brazil's Hypera SA is in initial talks about a plea deal, Brazil's Valor Economico newspaper reported on Wednesday, as the pharmaceutical company continues an internal probe into alleged corruption.

Oct 03 2018

Brazil's Hypera reports Q2 net profit of 278.8 mln reais

SAO PAULO, July 27 Quarterly profit at Hypera SA , Brazil's largest listed producer of over-the-counter medicine, rose 22.3 percent on a yearly basis in the second quarter as revenues increased more than 10 percent due to higher overall sales.

Jul 27 2018

Brazil's Hypera appoints committee to investigate after police raid

SAO PAULO, May 23 Brazilian pharmaceuticals company Hypera SA said on Wednesday that its board had appointed an independent committee to investigate alleged corruption by former executives.

May 23 2018

Brazil's Hypera in talks for leniency deal, could pay $540 mln fine -paper

SAO PAULO, May 17 Brazilian pharmaceutical company Hypera SA is in talks to agree to a leniency deal with prosecutors that could include a 2 billion reais ($540 million) fine, newspaper Valor Economico reported on Thursday, an agreement that Hypera denied.

May 17 2018

Earnings vs. Estimates